Finance

Lists
Why is CBIO up ५.५९%?
Dive Deeper
CBIO:NASDAQ
Crescent Biopharma Inc
US$ १४.९१
+५.५९%
(+०.७९) 1D
अक्टोबर ९, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
US$ १४.०७
High
US$ १५.२८
Low
US$ १४.०७
Mkt. cap
५५.३८ करोड
Avg. vol.
४.९४ लाख
Volume
१.००
52-wk high
US$ २७.४१
52-wk low
US$ ८.७२
EPS
-US$ ७.४१
Beta
१.२७
Shares outstanding
३.७१ करोड
No. of employees
६९
Open
US$ १४.०७
High
US$ १५.२८
Low
US$ १४.०७
Mkt. cap
५५.३८ करोड
Avg. vol.
४.९४ लाख
Volume
१.००
52-wk high
US$ २७.४१
52-wk low
US$ ८.७२
EPS
-US$ ७.४१
Beta
१.२७
Shares outstanding
३.७१ करोड
No. of employees
६९
News stories
From web sources and news partners
ChartMill
ChartMill
·
२२ मिनेट पहिले
Cavco Industries (NASDAQ:CVCO): A GARP Candidate With Growth at a Reasonable Price
Simply Wall Street
Simply Wall Street
·
२५ मिनेट पहिले
Immersion CEO, President & Chairperson Acquires 2.3% More Stock
Stocktwits
Stocktwits
·
२३ मिनेट पहिले
S&P 500’s Narrow Rally Faces Fresh Tests From CPI, Bank Earnings: 3 Charts To Watch This Week
Yahoo Finance
Yahoo Finance
·
५६ मिनेट पहिले
2 S&P 500 Stocks to Own for Decades and 1 We Ignore
About Crescent Biopharma Inc
CEO-
Employees६९
Founded२०२४
HeadquartersWaltham, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websitecrescentbiopharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current US$ १४.९१
US$ ३६.०० (+१४१.४५%)
Average
US$ २९.७५ (+९९.५३%)
Lowest
US$ २७.०० (+८१.०९%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
US$ २८.००
+८७.८%
10/06/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Upgraded
US$ ३६.००
+१४१.४%
10/06/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
US$ २८.००
+८७.८%
10/05/2026
Robert Driscoll
Wedbush
Buy
Maintained
US$ २७.००
+८१.१%
09/14/2026
Unknown Analyst
Wedbush
Buy
Maintained
US$ २७.००
+८१.१%
09/14/2026
Biren Amin
Piper Sandler
Buy
Maintained
US$ ३५.००
+१३४.७%
06/23/2026
Bradley Canino
Guggenheim
Buy
Maintained
US$ ३५.००
+१३४.७%
04/29/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
१.०८ करोड
१०.३९ लाख
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
२.०३ करोड
९.५० करोड
१.७९ करोड
१.९४ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५५.३८ लाख
७३.०९ लाख
७८.६५ लाख
८७.४३ लाख
Operating expense
२.५९ करोड
१०.२३ करोड
२.५८ करोड
२.८१ करोड
Total operating expenses
२.५९ करोड
१०.२३ करोड
२.५८ करोड
२.८१ करोड
Operating income
-२.५९ करोड
-९.१५ करोड
-२.४७ करोड
-२.८१ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-२.४६ करोड
-९.०४ करोड
-२.३३ करोड
-२.४८ करोड
EBT excluding unusual items
-२.४६ करोड
-९.०४ करोड
-२.३३ करोड
-२.६६ करोड
Income tax expense
-
२०.०० लाख
-
-
Effective tax rate
-
-२.२१%
-
-
Other operating expenses
-
-
-
-
Net income
-२.४६ करोड
-९.२४ करोड
-२.३३ करोड
-२.४८ करोड
Net profit margin
-
-८५२.०६%
-२,२४०.९०%
-
Earnings per share
-१.३७
-४.९२
-०.७०
-०.६२
Interest and investment income
१२.७८ लाख
१०.९५ लाख
१४.४६ लाख
१५.२७ लाख
Interest expense
-
-
-
-
Net interest expenses
१२.७८ लाख
१०.९५ लाख
१४.४६ लाख
१५.२७ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.५९ करोड
-९.१४ करोड
-२.४७ करोड
-२.८१ करोड
Gain or loss from assets sale
-
-
-
-१७.७० लाख
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू